Lv5
900 积分 2021-11-06 加入
Best practices for achieving consensus in HER2‐low expression in breast cancer: current perspectives from practising pathologists
4小时前
待确认
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
3天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
3天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
3天前
已完结
RAS-targeted therapies: is the undruggable drugged?
19天前
已完结
Treatment of NSCLC after chemoimmunotherapy - are we making headway?
2个月前
已完结
Treatment of NSCLC after chemoimmunotherapy - are we making headway?
2个月前
已完结
Biology and regulation of IL-2: from molecular mechanisms to human therapy
2个月前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
2个月前
已完结
PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program
2个月前
已完结
皖公网安备34019202002308
